Its an experimental drug being developed by pharmaceutical giant Eli Lily that early data suggests provides even better weight-loss outcomes than Ozempic
Semaglutide affects appetite regulation and slows the movement of food through the stomach
Caspase-1, as well as caspases -4, -5, and -11, cleave the substrate gasdermin D, releasing its N-terminal fragment
Kant R, Halder SK, Fernandez JA, Griffin JH, Milner R
Based on Kaiser formulary bulletins and member-reported experiences, most regions require the following before approving Wegovy: Clinical eligibility: BMI of 30 kg/m or greater, or BMI of 27 kg/m or greater with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea) Documentation that the member has participated in a Kaiser-affiliated lifestyle or behavioral weight-management program for a minimum of 3 to 6 months Lab work within the past 6 months including fasting glucose, HbA1c, lipid panel, and thyroid function Prescriber requirements: The prescribing physician must be a Kaiser-employed or contracted provider A referral to Kaiser's obesity-medicine or endocrinology department is typically required before the PA can be submitted The obesity-medicine specialist's notes must confirm medical necessity The clinical rationale for these layers traces back to the STEP-1 trial (N=1,961), which demonstrated 14.9% mean body-weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo
